17.05.2024  21:59:56 Zm. -0,38 Wolumen Bid- Ask- Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
24,97USD -1,50% 6 322
Obrót: 158 535,68
-Wolumen Bid: - -Wolumen Ask: - 273,43 mlnUSD 19,80% 2,74

Opis działalności

Medifast (NYSE: MED) is the leading easy-to-use, clinically proven provider of weight-loss and healthy living products and programs. Medifast aims to help customers lead a healthier lifestyle through a holistic approach to weight-loss and weight management, nutrition education and fitness. Medifast's proven results are based on the use of structured meal plans featuring Medifast Meals, which are nutritionally designed to assist customers with successful weight-loss and weight management. The company sells its products and programs via four unique distribution channels: 1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. The company also offers sports nutrition products under the brand Dual Fuel™ Nutrition that are formulated to provide athletes and active individuals with the right balance of carbohydrates and high quality protein for top performance. Medifast was founded in 1980 and is located in Owings Mills, Maryland.
 

Zarząd & Rada nadzorcza

CEO
Daniel Chard
Zarząd
James Maloney, Claudia Greninger, Jason L. Groves, Esq., Lauren Walker, Nicholas Johnson, Tony Tyree
Rada nadzorcza
Andrea B. Thomas, Constance J. Hallquist, Daniel R. Chard, Jeffrey J. Brown, Kevin G. Byrnes, Michael A. Hoer, Scott Schlackman, Xian Ming
 

Dane firmy

Nazwa: Medifast Inc.
Adres: 100 International Drive,Baltimore, Maryland 21202, USA
Telefon: +1-410-581-8042
Fax: -
E-mail: -
Internet: www.medifast1.com/
Przemysł: Służba zdrowia
Sektor: Przemysł Farmaceutyczny
Podsektor: Przemysł Farmaceutyczny
Koniec roku finansowego: 31.12
Free float: 65,90%
Data IPO: -

Relacje inwestorskie

Nazwa: Katie Turner
Telefon: +1-646-277-1228
Fax: -
E-mail: -

Główni akcjonariusze

Freefloat
 
65,90%
BlackRock, Inc.
 
14,70%
The Vanguard Group
 
10,70%
Renaissance Funds
 
8,70%